A clinician-focused review of semaglutide 2.4 mg dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, ethnicity-stratified trial data, and practical titration guidance.
A analysis of the evolocumab (Repatha) cancer risk signal, covering FOURIER trial data, long-term extension studies, mechanistic hypotheses, and current FDA and guideline positions on PCSK9 inhibitor safety.
When and how to restart Repatha (evolocumab) after acute illness, hospitalization, or surgery. Covers the evidence on LDL rebound, missed-dose pharmacokinetics, and step-by-step re-initiation protocol.
A complete guide to TRICARE coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, formulary tier, and how to appeal a denial. prepared by the HealthRX.com Editorial Team.
Does ezetimibe (Zetia) change appetite or food cravings? A deep dive into the pharmacology, clinical trial data, and patient reports that answer this question.
A clinician-level review of how finasteride is absorbed, metabolized, and excreted, plus an evidence-based look at its effects on energy expenditure, thermogenesis, and body composition.
Finasteride labels report sexual effects, not muscle outcomes. General training and protein evidence is from healthy adults, not finasteride users.
Evidence-based guidance on when and how to restart finasteride (1 mg or 5 mg) after acute illness, fever, surgery, or hospitalization. Covers hair loss regression, DHT rebound timing, dose re-titration, and red-flag conditions that require pausing therapy.
A deep dive into how finasteride works, its 5-alpha-reductase inhibition mechanism, oral dosing, and why injectable forms are not used in standard practice. Includes trial data, dosing tables, and clinical FAQs.
Find out whether TRICARE covers finasteride for hair loss or BPH, what prior authorization looks like, which formulary tier it sits on, and how to appeal a denial step by step.
A guide to finasteride dosing for men aged 18, 29, covering 1 mg AGA and 5 mg BPH protocols, fertility considerations, sexual side-effect data, and monitoring recommendations.
A clinician-level review of finasteride's interactions with autoimmune conditions, including immune-mediated hair loss, post-finasteride syndrome debate, and prescribing considerations for patients with lupus, psoriasis, or other autoimmune diagnoses.
A deep dive into finasteride microdosing for androgenetic alopecia, covering dose-response pharmacology, DHT suppression at sub-milligram doses, side-effect considerations, and what a clinician conversation about off-label dosing should cover.
A detailed look at Medicare Advantage coverage policies for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary status, appeal rights, and cash-pay alternatives for premenopausal women with HSDD.
Human trials of copper tripeptide GHK-Cu are small and topical. See why no post-surgical dose exists and where FDA stands on safety.
A guide to copper tripeptide GHK-Cu dosing in adults 65 and older, covering renal considerations, falls risk, drug interactions, and compounding pharmacy protocols.
A clinician-level review of copper tripeptide GHK-Cu and its documented effects on sleep architecture, including mechanisms, trial data, dosing context, and what remains unknown.
A clinical breakdown of 503A vs 503B pharmacy classifications, compounded GLP-1 legal status after the shortage resolutions, how to verify a legitimate pharmacy, and how compounded semaglutide and tirzepatide compare to brand-name Wegovy and Zepbound in safety and dosing.
A cross-trial comparison of PIONEER-1, PIONEER-4, PIONEER-6, and OASIS-1 examining oral semaglutide's A1C reduction, weight loss at 50 mg, cardiovascular non-inferiority, and gastrointestinal tolerability versus injectable GLP-1 agents.
A rigorous side-by-side comparison of STEP-1 (semaglutide 2.4 mg) and SURMOUNT-1 (tirzepatide 5/10/15 mg) for chronic weight management, covering matched outcomes, population differences, methodology gaps, and what the two trials together do and do not establish.
At 15 mg, tirzepatide cut weight 20.9% in obesity and 14.7% in type 2 diabetes; SURMOUNT-3 added 18.4% after a lifestyle lead-in.
A detailed guide to compounded semaglutide and tirzepatide legal status in 2025, covering the FDA shortage list, 503A vs 503B pharmacy rules, how to verify a compounding pharmacy, and safety differences between compounded and brand-name GLP-1 medications.
Real 2025 prices for Wegovy, Zepbound, Ozempic, Mounjaro, and compounded semaglutide. Covers list price, insurance, manufacturer savings cards, and compounded alternatives with clinical context.
Exact out-of-pocket costs for Zepbound, Wegovy, Ozempic, and Mounjaro in 2025, plus compounded GLP-1 pricing, insurance rules, and savings programs explained with clinical context.
What FDA says about compounded semaglutide and tirzepatide: approval status, adverse event reports, vial and shipping concerns, and pending action.
Sub-FDA-approved doses of semaglutide and tirzepatide are spreading through telehealth without RCT support. The HealthRX.com Medical Team argues that dose-finding rationale does not equal efficacy data, and that patients deserve that distinction made explicit.
Weight regain after semaglutide discontinuation is not a side-effect or a failure, it is the pharmacology. The HealthRX.com Medical Team argues the STEP-1 extension data obligates us to reframe GLP-1 agonists as chronic-disease therapy from the first prescription.
Evidence-based guide to maintaining weight loss long-term on GLP-1 receptor agonists, including what happens when you stop semaglutide or tirzepatide, how to taper, what the clinical trials say about weight regain, and how to switch between agents.
Mounjaro (tirzepatide) led to 20.9% average weight loss at 72 weeks in trials, outperforming semaglutide. See dosing, FDA status, and how it compares.
Ozempic face is the gaunt, sagging appearance that can follow rapid GLP-1-driven weight loss. Learn the physiology behind facial volume loss, the protein and resistance-training targets that limit it, and when filler or skin-tightening procedures are appropriate.
A clinical deep-dive into why GLP-1 receptor agonist weight loss slows or stops, with evidence-based strategies for titration adjustment, missed-dose management, microdosing, and long-term maintenance dosing.
A guide to switching between semaglutide, tirzepatide, liraglutide, and other GLP-1 medications. Covers tapering, bridging, weight regain risks, and long-term maintenance strategies backed by clinical trial data.
How semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) titration schedules work, what to do about missed doses and weight-loss plateaus, and where FDA labeling ends and individualized clinical judgment begins.
A guide to verifying GLP-1 pharmacies in 2025. Covers 503A vs. 503B compounding rules, FDA shortage list status, how to spot illegal vendors, and the safety data behind brand-name semaglutide and tirzepatide.
No trial tested switching from Ozempic or Wegovy to Mounjaro. Head-to-head and stopping trials of tirzepatide and semaglutide are summarized.
Telehealth providers cannot guarantee a specific GLP-1 prescription before a clinical evaluation. Learn why, what factors guide Wegovy® vs. Alternatives, and how to get the right medication for your situation.
A complete guide to BCBS Arizona coverage for liraglutide (Saxenda), including formulary tiers, prior authorization requirements, step therapy rules, and how to appeal a denial.
A breakdown of FDA guidance on Ozempic (semaglutide injection): approved indications, dosing schedules, contraindications, label warnings, and how telehealth programs like Calibrate use the drug within those rules.
A comparison of prescription and OTC weight loss drug costs in the US, including generics, compounded semaglutide, and brand GLP-1s, with a framework for weighing price against expected effect.
Saxenda requires a BMI of 30+, or 27+ with a condition like diabetes or high blood pressure. Adolescents 12-17 may also qualify. See full criteria.
Find out whether Anthem Blue Cross Blue Shield covers Saxenda (liraglutide) for weight loss, what prior authorization requirements typically apply, and what to do if coverage is denied.
Learn why September is PCOS Awareness Month, what polycystic ovary syndrome is, how it is diagnosed and treated, and what you can do to manage symptoms year-round.
Heavy periods, pelvic pressure, frequent urination, and back pain can all point to uterine fibroids. Learn how to tell, what the research says, and when to act.
A guide to improving scalp health and stimulating hair growth, covering evidence-based topicals, nutritional factors, scalp care routines, and when to seek medical treatment.
Understanding your personal diabetes risk score can trigger early intervention, prevent type 2 diabetes entirely, or delay its onset by years. Learn which tools to use, what the numbers mean, and what to do with your results.
CJC-1295 raises GH and IGF-I in healthy adults, but its effect on GH stimulation test results has not been studied.
STEP 1 reports only weight outcomes for Wegovy 2.4 mg. Smaller semaglutide studies on fasting insulin and HOMA-IR are mixed.
Rexulti lactation data is limited, with Hale risk category and milk transfer factors explained so you can review options with a lactation-trained clinician.
Compare Leqvio (inclisiran) with statins and PCSK9 antibodies, including how each works, its dosing schedule and LDL-C results from ORION trials.
In pooled adult trials of Leqvio, the main difference from placebo was injection-site reactions (8% vs 2%), with other adverse events generally similar.
A comprehensive clinical guide to diabetic retinopathy covering how chronic hyperglycemia damages retinal vessels, the four ETDRS stages, screening intervals, laser and anti-VEGF treatments, and the HbA1c targets that cut progression risk.
Learn how to calculate your insulin-to-carb ratio (ICR), verify it with real-meal tests, adjust for correction factors, and integrate it into basal-bolus and pump regimens. guidance with primary-source citations.
A guide to metformin-associated lactic acidosis (MALA): real incidence rates, who is at risk, FDA contraindications, drug interactions, and when to hold or stop the drug safely.
NPH insulin peaks in 4 to 12 hours and lasts up to 24, while regular insulin acts faster and clears sooner. See dosing and OTC options like Humulin N.
Prandin (repaglinide) lowers HbA1c by 1.5-2.0 points with less hypoglycemia risk than glipizide. See dosing, mechanism, and how it compares to other diabetes drugs.
A guide to insulin degludec (Tresiba) safety in adults aged 30 to 49, covering hypoglycemia risk, cardiovascular data from DEVOTE, injection-site reactions, drug interactions, and practical dosing guidance.
A guide to the Adderall XR caffeine interaction profile, covering cardiovascular risks, CNS stimulant overlap, timing strategies, and when to call your prescriber.
A guide to the Adderall XR and iodinated contrast dye interaction, covering cardiovascular risks, metformin co-prescribing, pre-scan protocols, and when to hold your dose.
A deep dive into the Adderall XR and nicotine interaction profile, covering pharmacokinetics, cardiovascular risks, appetite suppression, and practical clinical guidance.
A breakdown of the Adderall XR and SNRI interaction, covering serotonin syndrome risk, blood pressure effects, CYP2D6 pharmacokinetics, monitoring parameters, and when the combination is manageable vs. Contraindicated.